Supplemental Digital Content 3

TABLE: Safety and Laboratory Assessments

		Treatment visits					Follow up visits	
Assessment	**Baseline**	**Day 1**	**Days 2 and 3**	**Days 4 and ≤15**	**EOIV**	**EOT†**	**TOC**	**LFU**
Complete blood count with differential, chemistry panel, CrCL calculation, ESR, and optional CRP	X	If clinically indicated	If clinically indicated	X‡	X§	If clinically indicated	X¶	If clinically indicated
Urine or serum pregnancy test	X						X	
Urine sample routine analysis	X			If clinically indicated				
Intra-abdominal fluid collection for culture	X			If clinically indicated				
Blood sample for culture‖				If clinically indicated				
Blood for PK analysis††			X					

†Oral therapy only. ‡Conducted on Day 7 if patient was still on IV study drug at that time. §If EOIV occurred within 48 hours after these assessments were performed on study Day 7, they were not repeated. ¶Performed at TOC only if patient had an abnormal (high/low flag) result on or after EOIV. ‖Obtained if clinically indicated and not already collected per standard of care. ††Blood samples were taken in a manner such that the blinded observer remained blinded.

Safety and laboratory tests were performed at a local laboratory at or near the investigator site.

CrCL, creatinine clearance; CRP, C-reactive protein; EOIV, end-of-intravenous treatment; EOT, end-of-treatment; ESR, erythrocyte sedimentation rate; IV, intravenous; LFU, late follow-up; PK, pharmacokinetic; TOC, test-of-cure